Quarter of firsts: the period's story is built from first-time events the company has never done before, now starting to
The model's full reasoning — Q4 2022 call → NOWe need to determine if management's account of the just-reported period is built substantially around first-time events that are genuine firsts, already accomplished, and presented as beginnings with repetition already forming. The call is Q4 2022 earnings. We need to look for at least two distinct first-time events that management describes as new territory for the company, and that they are presented as the front of something continuing. Let's scan the transcript for first-time events. Key phrases: "first", "new", "never", "initial", "first time", "first-in-human", "first approval", "first launch", etc. From Len's opening: "We also made several important advances across our pipeline during the quarter, notably the submission of a Biologic License Application for aflibercept 8 milligrams in neovascular age-related macular degeneration or wet AMD as well as diabetic macular edema, or DME, positioning us for a potential U.S. launch in late August of this year." That's a submission, not a first-time event that has occurred. It's a plan. "Additionally, we received FDA approval for Libtayo in combination with chemotherapy as a first line treatment for advanced non-small cell lung cancer, making Libtayo only the second PD-1 or PD-L1 antibody approved in this setting, regardless of the patient’s histology or PD-L1 expressions level." That's an approval, a first for Libtayo in that indication. But is it a first-time event for the company? It's a new approval, but it's a regulatory approval, not a commercial transaction. However, it is a first-time event in the sense that Libtayo is now approved for a new indication. But is it presented as a beginning with repetition? Possibly. "We also presented data from our rapidly advancing oncology pipeline, including fianlimab, our LAG-3 antibody in combination with Libtayo in advanced non-small cell lung cancer, odronextamab, our CD20xCD3 bispecific in B-cell lymphomas and linvoseltamab, our BCMA x CD3 bispecific in multiple myeloma." That's data presentations, not firsts. "Finally, Dupixent was approved for prurigo nodularis in Europe." That's an approval. Then Len talks about strategic imperatives. He mentions "aflibercept 8 milligrams has the potential to change the treatment paradigm" - that's future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
CUBI · Q3 2018 → YESThe question is: Does management's account of the just-reported period built substantially around FIRST-TIME EVENTS that the company had NEVER DONE BEFORE, treating them as the OPENING INSTANCES of ac...YES The transcript shows two clear first-time events that management presents as the start of ongoing activity: the launch of the CB digital bank (first direct bank for high-net-worth customers, already generating $52–100 million monthly core deposits) and the launch of consumer loan offerings with Upstart (first partnership, with consumer loans expected to grow into a larger part of the earning asset base over 12–18 months). These are framed as new territory for the company, with repetition already forming through sustained deposit inflows and expanding loan contributions. Other items like securities sales and deposit improvements are supportive but secondary to these launches in the period’s narrative.
GIII · Q4 2024 → YESThe question is about whether management's account of the just-reported period is built substantially around FIRST-TIME EVENTS that the company had NEVER DONE BEFORE, treated as opening instances of a...YES The transcript shows management's account centered on multiple genuine first-time events from the recent period, treated as openings with repetition forming: - Launch of Donna Karan collection (first commercial deployment of the iconic brand), supported by the largest marketing campaign ever for G-III and new fragrance launch. - Nautica Jeans launch this spring with 200+ doors. - First-ever beach club and restaurant for Vilebrequin in Cannes. - First five-star luxury hotel in Macau for Karl Lagerfeld. - Newly opened Paris location and first market for Champion outerwear.
ADSE · Q4 2021 → YESThe question is about whether management's account of the just-reported period is built substantially around FIRST-TIME EVENTS that are genuine firsts already accomplished, and presented as beginnings...